Clin2
NCT05152797Possibly a fitNot yet recruiting

Study immune-cell therapy for advanced gynecologic and breast cancers

Tumor Infiltrating Lymphocytes

Treatments studied

Part of Cancer, Women’s health & pregnancy clinical trials.

This Phase 1/2 study tests a treatment using tumor-fighting immune cells taken from your cancer (TILs) for certain advanced or metastatic cervical, ovarian, endometrial, or breast cancers. It may help shrink tumors and will track safety, especially in people who have already tried standard treatments.

Summary written for real people, not researchers, by Clin2.

Phase
Phase 1/Phase 2
Enrollment
91 people
Ages
18 years to 75 years
Study type
Interventional

Who can take part

  • Be between 18 and 75 years old and sign informed consent
  • Have advanced or metastatic cervical, ovarian, endometrial, or breast cancer confirmed by scans and pathology
  • Have had at least two prior chemotherapy treatments (or your cancer cannot be cured with surgery/radiation)
  • Have at least one tumor spot that doctors can remove (resect) to collect immune cells, at least 1.5 cm after removal
  • Be healthy enough for treatment based on blood counts and heart/liver/kidney tests, with no serious organ problems
  • Not have had an organ transplant or any prior cell transfer therapy; no autoimmune disease and no immune-suppressing steroid medicines

View the official record on ClinicalTrials.gov

Quick eligibility check

Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.

Similar studies

Other trials that look related to this one.

NCT05087745Recruiting· Early Phase 1
TIL therapy for advanced solid tumors

This trial tests a treatment that uses your own immune cells, called TILs, to fight advanced solid tumors. The cells are taken from a biopsy of your tumor, multiplied in a lab, and then given back to you. It might help if you have tried other treatments without success, or if no standard treatment is available.

Hangzhou, Zhejiang
NCT05142475Recruiting· Early Phase 1
Study of GC101 tumor-infiltrating cells for advanced breast cancer

This early-phase study tests an experimental cell therapy made from your tumor’s immune cells (TILs) for advanced breast cancer. It may help shrink tumors or improve how long people stay in remission, but it’s still being studied for safety and effectiveness.

Shanghai
NCT05098171Recruiting· Early Phase 1
Study TIL cell therapy for advanced gynecologic cancers

This early-phase study tests GC201 TIL therapy, made from your tumor’s immune cells (TILs), for advanced or returning gynecologic cancers. If standard treatments have already failed—or there aren’t standard options—this trial may offer a new way to train your immune system to fight the cancer.

Shanghai, Shanghai Municipality
NCT04967833Recruiting· Early Phase 1
Testing TIL cell therapy for advanced solid tumors

This trial tests a type of immune cell treatment called TIL (tumor-infiltrating lymphocytes) in people with advanced solid cancers. It may help your immune system better recognize and attack tumors, especially if standard treatments have not worked.

Shanghai
NCT06088472Recruiting· Phase 1
TIL therapy for advanced solid tumors

This trial tests a treatment made from your own immune cells (TILs) that are taken from a tumor, grown in a lab, and then given back to you to fight cancer. It's for people with solid tumors that have spread or come back after treatment.

Xuzhou, Jiangsu
NCT05098197Recruiting· Early Phase 1
Study of TIL cell therapy for advanced liver, bile, or pancreas cancer

This trial studies a treatment called TIL therapy, which uses your own immune cells grown from a tumor sample, to treat advanced cancers of the liver/bile ducts or pancreas. It’s mainly for people whose standard treatments have already failed (or none exist), and who can safely provide tumor tissue for the cell preparation.

Shanghai, Shanghai Municipality

Hear when a new Tumor Infiltrating Lymphocytes trial opens

We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.